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This paper looks at attempts that have been made to develop legal regulatory frameworks for modern 
biotechnology. The discussion is limited to the regulation of Genetically Modified Organisms (GMO) 
technology by the two leading producers and exporters of GMOs in Africa: South Africa and Kenya. The 
international and regional regulatory regimes are analysed for comparative purposes since the two 
countries have partially based their regulatory frameworks on these regimes. The methodology used is 
analytical; the challenges that are posed by GMO technology are analysed from public policy and legal 
perspectives. The main argument that is advanced is that the challenges that are frequently viewed 
merely as problems ought to be considered as indicators of possibilities and limits in regulating this 
fluctuant field. Ideas on the factors to be considered in developing appropriate regulatory frameworks 
for biotechnology are put forth to serve as a wake up call to policy makers and legislators that have to 
deal with such issues. It is concluded that a holistic approach should be used in addressing the 
pressing issues that are raised by biotechnology generally and GMOs in particular. 
 





Advances in biotechnology often present both opportuni-
ties and challenges to the regulatory authorities. How-
ever, the analysis of such advances “is almost always 
focused on the challenges rather than the opportunities 
(UNCTAD Secretariat, 2000). Pessimistic pictures are 
often painted particularly with regard to agricultural 
biotechnology. In South Africa, the general public tends 
to view biotechnology as being synonymous with geneti-
cally modified organisms (GMOs) (Montari et al., 2004). 
This is as a result of common local and international 
media reports. It is thus not surprising to come across 
sensational media reports such as “GM technology fails 
local potatoes” (Gathura, 2004), “GM mosquito not fit 
enough”, (McDowell, 2004) and “Activists angry at 
Genetically Modified Food Changes” (Kahn, 2004). 
The worrying situation is that the general approach in 
dealing with biotechnology and genetically engineered 
crops “tends to be portrayed in an antagonistic manner, 
leaving little room for constructive discussion. As a result, 
little opportunity exists for efforts to achieve a balance 
between factors such as the different needs of the public 
sectors, the complex requirements of farming 
systems…and the continuous pressure to achieve food 
security in developing countries” (Cohen et al., 2004). 
Scholars have equally joined in propagating the 
pessimistic attitude, for example, one of the recently 
published text books containing a series of chapters on 
biotechnology is entitled “Biotechnology- the Making of a 
Global Controversy (Bauer et al., 2002) and a short 
article which appeared in the New Jersey Law journal 
soon after Merck & Co. announced the withdrawal of “its 
blockbuster arthritis drug vioxx because it could increase 
the risk of heart attacks and strokes” bore the sensational 
title; “Vioxx Becomes a Class Act” (O’Brien, 2004). 
The main argument that is advanced in this paper is 
that the incidents that are viewed merely as problems 
and challenges ought to be considered as indicators of 
possibilities  and  limits in regulating this fluctuant field. In 





essence, the paper is a wake up call to policy makers 
and legislators that have to deal with such issues to use a 
holistic approach in addressing the pressing issues that 
are raised by biotechnology generally and GMOs in 
particular. 
The paper briefly looks at attempts that have been 
made to develop legal regulatory frameworks for modern 
biotechnology. The discussion is limited to the regulation 
of GMO technology in two countries: South Africa and 
Kenya. The international and regional regulatory regimes 
are briefly mentioned to pave way for the discussion 
because the two countries have partially based their 
regulatory frameworks on these regimes.  
The main reasons for choosing South Africa and Kenya 
are: they are among the leading producers and exporters 
of GMOs in Africa (Joroghe, 2001) and they are currently 
grappling with the development of legal regulatory 
frameworks for biotechnology. The South African 
situation is very useful for the discussion since the 
process of developing a regulatory framework for 
biotechnology has been marked by contracted debates 
and even litigation (Biowatch South Africa, 2004a). 
 
 
ISSUES AND CONCERNS IN THE REGULATION OF 
BIOTECHNOLOGY 
 
The prevailing situation of pessimism and antagonism 
may, arguably, be attributed to the fact that the laws and 
regulations that govern such advances have not been 
effectively developed. This is evident from the fact that 
the current legal frameworks are beset by the following 
problems: 
 
The legislative processes leading to the enactment of 
laws and regulations are often splintered 
 
Many organisations, which have different focal points, are 
involved in the process. Examples of such focal points 
are: biosafety (the need to protect human health and the 
environment from the possible adverse effects of the 
products of modern biotechnology), biodiversity and 
public health concerns. Two examples can be used to 
illustrate this: First, Article 5 of the Biosafety Protocol 
does not deal with the transboundary movement of living 
organisms, which are pharmaceuticals for humans. This 
omission was well intentioned as it was aimed at avoiding 
duplication of efforts since the World Health Organisation 
(WHO) would deal with such issues. The reality however 
is that WHO does not deal with biosafety or biodiversity 
issues and in any case it can only issue recommenda-
tions. 
The second example concerns the introduction of 
genetically modified maize in Kenya, which was initially 
targeted for the year 2008 but will be delayed for a further 
two years till 2010. The reason for the delay is that safety 
regulations  for   the   Insect  Resistant   Maize  for  Africa  




(IRMA) project have to be revised to bring them in line 
with national and international standards by focusing on 
the probable threats that GM maize could pose to human 
health and the environment (Chege, 2004). Interestingly, 
the regulatory issues were not exhaustively covered in 
the original project plan (Chege, 2004).  The project is a 
joint venture between the Kenyan government and 
international research institutes and it aims at developing 
a variety of maize that is able to resist attack by stem 
borers and major insect pests. Some of the donors, 
particularly the Rockefeller Foundation, are hoping that 
the inclusion of extra regulations will not slow the pace of 
the project. Joe DeVries of the Rockefeller Foundation 
was quoted as saying “it is clear that [this type of GM] 
maize has been tested and proven to work elsewhere 
hence there is no need for unnecessary regulations” 
(Chege, 2004). It is interesting to note that while the 
donors are more concerned with the expeditious comple-
tion of the project, the government regulator (the Kenya 
Plant Inspectorate Service) and IRMA are more concern-
ed with broader issues such as breeding, facilities, per-
mits and the social as well as economic implications of 
introducing GM maize to Kenyan farmers. This precaut-
ionary measure is understandable given the fact that the 
failure of GM potato in Kenya is still fresh in mind. Critics 
used this failure to confirm their fear that “bio-engineered 
techniques tried elsewhere may not be replicated in 
Africa with similar results” (Gathura, 2004). The initial 
gene construct for the potato was done at the Monsanto 
laboratories, in USA, using virus resistant technologies 
and was imported to Kenya in 2001. It took Monsanto 
nine years to develop a coat protein responsible for virus 
resistance. This was donated to Kenya Agricultural 
Research Institute (KARI) royalty free (Gathura, 2004). 
 Mock trials were initiated in five provinces (Western, 
Nyanza, Central, Coastal and Eastern). Subsequent local 
investigations proved that the technology had failed to 
produce a virus resistant strain. It is yet to be determined 
“whether the gene expression was adequate or it failed to 
address the diversity of virus in this region or just that the 
gene construct was inappropriate” (Gathura, 2004). 
 
Decentralised organisational framework with govern-
mental and intergovernmental organisations having 
overlapping jurisdictions 
 
A clear example of this situation is the administrative 
structure that is provided for under the Biosafety Bill of 
Kenya. Clause 5(1) establishes an administrative 
authority known as “the National Biosafety Authority”. The 
board members of the authority mainly consist of 
government officials from the eight regulatory agencies 
that are stipulated in the First schedule to the Bill viz., 
Ministry of Health, Department of veterinary services, 
Kenya Bureau of Standards, Kenya Plant Health 
Inspectorate Services, Kenya Industrial Property Office, 
Kenya wildlife Services, Pest Control Products Board and 
   




the National Environmental Management Authority 
(NEMA). Other members are drawn from both public and 
private sector.  
Section 3 of South Africa’s Genetically Modified 
Organisms Act also establishes a council known as the 
Executive Council for Genetically Modified Organisms. 
The council comprises of not more than eight members 
(the proposed amendment Bill provides for ten members- 
under Clause 3 (a)) drawn from diverse government 
departments viz., the Department of Agriculture, the 
Department of Arts, Culture, Science and Technology, 
the Department of Environmental Affairs and Tourism, 
the Department of Health, the Department of Labour and 
the Department of Trade and Industry. 
The establishment of one national authority is in line 
with the provisions of Article 19 of the Cartagena 
Protocol, which requires parties to designate one national 
focal point to be responsible on its behalf for liaison with 
the Secretariat. The manner in which the diverse 
regulatory authorities are incorporated into the national 
authority and council, in Kenya and South Africa 
respectively, may be a commendable way of ensuring 
that the overlap in their respective jurisdictions does not 
lead to overregulation. This is the case in view of the fact 
that each of these government departments is charged 
with the responsibility of administering other Statutes that 
may impact on GMOs. Conflicts may however arise due 
to overlaps in such authorities’ jurisdictions. An illustration 
of this is the inherent conflict between South Africa’s 
section 78(1) of the Biodiversity Act and the GMO Act. 
The said section of the Biodiversity Act provides that no 
permit for release of GMO should be issued in 
circumstances where the Minister of Environmental 
Affairs and Tourism believes that it may pose a threat to 
the environment or any indigenous species unless a prior 
Environmental Impact Assessment (EIA) has been 
conducted. The Minister is expected, under section 78(2), 
to convey such belief to the authority that is charged with 
the responsibility of issuing permits under the GMO Act. 
The lacuna in this regard is that there is no provision in 
the GMO Act, which requires the Minister to be notified 
before applications for release are granted under the 
GMO Act. 
Interestingly, there are many issues that regulatory 
authorities have to contend with. These are: the comple-
xity of biotechnology, fiscal restraints and globalisation. 
Each of these issues is explained below. 
 
Complexity of biotechnology: Regulation is a matter of 
“assignment of authority to a decision-making body that is 
in a position to make decisions based on the facts of the 
particular cases that are presented to them” (Dworkin, 
1996). The facts in question may originate from any 
sector of the society and the assignment of authority is 
usually done through legal structures or institutions. The 
vital role of law in the regulation of biotechnology in this 





agencies that are duly empowered to deliberate on the 
issues at stake.  
The regulation of activities related to biotechnology 
requires economic and social trade-offs because the 
issues that law seeks to regulate are also subject to other 
processes that influence the operation of law. Law must 
reckon with the societal spheres that constitute the 
‘environment of biotechnology’. The societal spheres in 
this context consist of the active roles that “economic, 
legal, mass media, political…” and other factors play in 
setting the agenda for the debates (Bauer et al., 2002).  
Modern biotechnology is equally characterised by 
scientific uncertainty and there are competing goal 
valuations. The different societal spheres focus on 
different aspects of biotechnology at different times and 
they have their particular logical approaches which may 
lead them to pay attention to totally different issues. For 
example: Economists may focus on different economic 
issues such as investment opportunities and stock 
market performance. The media focuses on the ‘news’ 
value of particular developments such as novelty, human 
interests or scandal. The important role that this sphere 
plays in framing issues in the public domain should not 
however be disregarded. Law focuses on rights and 
duties, safety of the advances, access to the products or 
information relating to biotechnology and benefit sharing. 
Public policy making (particularly in science) “involves 
setting directions and priorities, establishing and assuring 
ethical and safe standards for the conduct of scientific 
and technological products” (Holman et al., 1978).  
The regulatory authorities in question may have roles 
in different capacities ranging from fostering investment 
in research and development, maintaining amicable 
international economic relations and protecting their 
respective governments’ citizens from any harm that may 
arise from the products of biotechnology. Such diverse 
roles may give rise to conflict of interests. A clear 
illustration of this situation is the manner in which many 
European countries reacted to the emergence of the 
biotechnology industry in the 1990s: “The state’s role was 
perceived to be restricted to providing a congenial 
environment for industrial performance, and it was no 
longer considered appropriate for the state to promote 
other social goals when regulating biotechnology” 
(Bongert, 2002). 
 
Fiscal restraint: Regulation of any activity that affects 
the public is often costly in terms of setting up the 
necessary institutional frameworks. Though regulations 
have the advantages of laying down standards directly, 
avoiding complexity and having an apparent fairness, 
law-making “is a lengthy and costly procedure” (Govern-
ment of the Republic of Kenya). Such regulatory costs 
may have spillover effects on the consumers and tax 
payers. Regulations can equally “be expensive to monitor 
and enforce. They quickly become outdated and require 
frequent and expensive revisions” (Government of the 
Republic of Kenya).  





Globalization: The main challenges of globalisation are 
Lack of frameworks for coordinated action in the 
regulation of biotechnology; institutional overload and 
inability to agree and set priorities. This is evident from 
the manner in which various regions and nations have 
resorted to using diverse regulatory standards that take 
into consideration their unique concerns because, in 
some cases, they may not find the recommended 
international standards suitable for such concerns. 
 
 
THE LEGAL REGULATORY FRAMEWORKS IN PLACE  
 
The development of legal regulatory frameworks has 
been marked by adoption of new legislation and 
amendment of older laws to respond to the new 
challenges (FAO’s Legislative Study, 2003). This is the 
case since legislation essentially deals with biosafety, 
food safety and consumer protection in respect of which 
either new legislation is needed or existing legislations 
should be amended. 
Most regulatory instruments have focused on GMOs, 
as there is a lot of ongoing debate in this area. FAO’s 
Legislative study clearly captures the nature of law that 
governs modern biotechnology: 
 
 “Biosafety instruments represent the primary source 
of law on modern biotechnology in the world today. 
Biosafety instruments address the risks posed to the 
environment and human health when GMOs are 
released into the environment either for research 
(e.g. small scale or field-testing) or for commercial 
purposes. Biosafety instruments also address 
contained use of GMOs.” 
 
There is however no single comprehensive legal 
instrument that addresses all aspects of GMOs or the 
products of modern biotechnology at the international 
level. The frameworks in place consist of binding instrum-
ents and non-binding policy documents. A brief descrip-





A number of international legal instruments govern 
biotechnology at this level as shown in Table 1. Non-
binding documents are not included in the table as, 
strictly speaking they may not be considered to be part of 
the legal framework. Two instruments that specifically 
deal with GMOs, and have greatly influenced the national  
frameworks under  discussion,  are  the  Convention  on 
Biological Diversity and the Cartagena Protocol. 
 
 
The Convention on Biological Diversity (CBD) 
 
The Convention on Biological diversity was finalised in 
May 1992 and entered into force on 29th December 1993.  




It is the main international instrument that addresses 
biodiversity issues (Cartagena, 2000). It addresses two 
main issues with regard to biotechnology: “it provides for 
access to and transfer of technologies, including biotech-
nology and ensures the development of appropriate 
procedures for enhancing the safety of biotechnology in 
the context of the Convention’s overall goal of reducing 
all potential threats to biological diversity” (Cartagena, 
2000). 
Article 8(g) of the Convention provides for a general 
framework under which contracting parties have attempt-
ted to develop regulations to govern biotechnological 
advances. The article provides as follows:  
 
“Each contracting party shall as far as is possible 
and appropriate…Establish or maintain means to 
regulate, manage or control the risks associated 
with the use and release of living modified 
organisms resulting from biotechnology which are 
likely to have adverse environmental impacts that 
could affect the conservation and sustainable use of 
biological diversity, taking into account the risks to 
human health.”  
 
 
The Cartagena Protocol on Biosafety to the Conven-
tion on Biological Diversity (Biosafety Protocol) 
 
The protocol was finalised and adopted on 29th January 
2000. It came into force in September 2003. It was 
developed pursuant to Article 19, paragraph 3 of the 
CBD, which “sets the stage for the development of an 
international legally binding instrument to address the 
issue of biosafety.” It aims at reconciling “the respective 
needs of trade and environmental protection with respect 
to a rapidly growing global industry, the biotechnology 
industry.” It, arguably, “creates an enabling environment 
for the environmentally sound application of biotechno-
logy, making it possible to derive maximum benefit from 
the potential that biotechnology has to offer, while 
minimising the possible risks to the environment and to 
human health.” 
The Protocol’s salient features are: 
 
• It advocates for the application of precautionary 
principle, which requires appropriate decisions to be 
made irres-pective of the fact that scientific information 
regarding the adverse effects of a living modified 
organism is insufficient (Articles 1, 10(6) and 11(8)). 
• It encourages parties to take necessary and 
appropriate legal, administrative and other measures to 
implement the obligation of the Protocol (Article 2). 
• It respects state parties’ sovereignty particularly with 
regard to their obligations under international law.  
• It does not apply to the transboundary movement of 
living modified organisms which are pharmaceuticals 
for humans insofar as they are governed by other 
relevant international agreements or organisations 
(Article 5). 
   




Table 1. Binding international regulatory instrument for biotechnology. 
 
 Regulatory instrument Relevance to biotechnology 
1 The United Nations Convention on the Law of the Sea (1982) Limited to pollution of the marine environment. 
2 Convention on Biological Diversity (CBD) (1992) Very relevant as it governs “the conservation of biological 
diversity, the sustainable use of its components and the fair 
and equitable sharing of the benefits arising out of the 
utilisation of genetic resources” (Article 1). 
3 The World Trade Organisation’s (WTO Agreement on the 
Application of Sanitary and Phytosanitary Measures (1994) 
Quite relevant as it provides for the enactment of laws, 
decrees, regulations, requirements and procedures relating to 
sanitary and phytosanitary concerns that may affect trade. 
4 The WTO’s Agreement on Technical Barriers to Trade (1994) Provides for standards of ensuring the elimination of 
unfavourable treatment of trading member countries’ products. 
This is relevant to biotechnological industrial and agricultural 
products. 
5 The UN Food and Agriculture Organisation (FAO) International 
Plant Protection Convention (IPPC) (1997) 
Aims at securing “common & effective action to prevent the 
spread and introduction of pests of plants and plant products 
and to promote measures for their control” (Article 1). 
6 Convention on Access to Information, Public Participation in 
Decision-making and Access to Justice in Environmental 
Matters (1998) 
Protects the right of every person of present and future 
generations to live in an environment adequate to his/her 
health and well being and guarantees the rights of access to 
information, public participation in decision-making & access to 
justice in environmental matters.  The convention is thus 
applicable to any biotechnological advances that may impact 
on the environment. 
7 The CBD Cartagena Protocol on Biosafety (2000) Aims at “ensuring an adequate level of protection in the field of 
safe transfer, handling and use of living modified organisms 
resulting from modern biotechnology that may have adverse 
effects on the conservation and sustainable use of biological 
diversity, taking also into account risks to human health, and 
specifically focusing on transboundary movements” (Article 1). 
8 The International Treaty for Plant Genetic Resources for Food 
and Agriculture (2001) 
Deals with the conservation and sustainable use of plant 
genetic resources for food and agriculture and equitable 




The suitability of the regulatory environment enshrined in 
the protocol is contentious. The specific contentious 





To pave way for a discussion of the selected national 
frameworks, this section is limited to the African region as 




THE AFRICAN MODEL LAW ON SAFETY IN 
BIOTECHNOLOGY 
 
The model law was endorsed at the meeting of the 
African Union in Maputo in August 2003. It is more 
comprehensive than the Cartagena Protocol insofar as it 
applies to “import, export, transit, contained use, release 
or placing on the market of any genetically modified 
organism whether intended for release into the 
environment, for use as pharmaceutical, for food, feed or 
processing or a product of a genetically modified 
organism” (Article 2). The provisions of the Model Law 
have been influenced by the Biosafety Protocol but it 
adopts “more protective measures than the agreed 
minimum set out in the protocol” (Mayet, 2003). Some of 
the   additional   protective   measures   are   summarised 
below. 
 
• It requires that advanced informed agreement (AIA) 
procedure be applied to all categories of GMOs, products 
of GMOs and their uses. It is interesting to note that the 
Biosafety Protocol only requires the AIA procedure to 
apply outright to the first time a GMO is imported for 
direct introduction into the environment of the importing 
party. 
• Mandatory labeling and identification (Article 11). 
• Traceability for GMOs and genetically modified food. 
• Liability and redress for harm caused by GMOs to 
human health, the environment and resultant economic 
loss (Article 14). 
 
It is stated in the Preamble that the precautionary 
principle should be applied to activities relating to  GMOs, 
   




Table 2. Regulatory instruments for biotechnology in South Africa. 
 
 Statute Scope Relevance to biotechnology 
1. The Genetically Modified 
Organisms Act No. 15 of 1997 
Applies to the genetic modification of 
organisms and development, production, 
release, use and application of genetically 
modified organisms as well as the use of 
gene therapy (Section 2). 
Provides for measures to promote responsible 
development, application and use of GMOs. It 
appears to be more focused on biosafety 
issues. 
2. The Environment Conservation 
Act, No. 73 of 1989 
Provides for mandatory requirements for 
Environmental impact assessment for GMOs. 
Limited scope 
3. The Foodstuffs, Cosmetics and 
Disinfectants Act, No. 54 of 1971 
Sets out control measures to ensure food 
safety. 
Limited scope as it may be deemed to require 
clear labeling of GMOs only. 
4. The national Environmental 
Management Act No. 107 of 
1998 
Sets down minimum standards for decision-
making in environmental management 
 Appears to be limited to the provision of 
incentives to civil society to monitor 




which are within the scope of the Model Law. This 
approach is consistent with Article 8(g) of the CBD, which 
requires parties to regulate and manage risks associated 
with GMOs and products of GMOs. In view of its broad 
scope, the Model Law has been commended as a “piece 
of Legislation drafted by Africans for Africa, taking into 




Selected National frameworks: 
 
FAO’s Legislative study established that at the national 
level, “there does not appear to be any single law 
addressing all aspects of biotechnology. Instead, the 
primary focus is on GMOs.” A clear illustration of this is 
the situation obtaining in South Africa and Kenya that are 
currently grappling with the development of legal 
frameworks for the regulation of biotechnology. The 
ongoing developments in these countries are discussed 





The South African situation is interesting insofar as it was 
the first African country to approve transgenic crops 
forcommercial purposes and is the leader in agricultural 
biotechnology research and development on the 
continent (Joint Report, 2002). It “started to address 
issues related to genetic engineering as early as the late 
1970s through the establishment of the South African 
Genetic Experimentation Committee (SAGENE) as the 
national advisory body on biotechnology research and 
development.” An attempt has been made to develop a 
national biotechnology strategy in which it is acknowled-
ged that “it is the government’s responsibility to ensure 
that new biotechnology products or services do not 
threaten the environment or human life or undermine 
ethics and human rights” (National Biotechnology 
Strategy for South Africa, 2001). 
In view of the foregoing, South Africa has been 
correctly described as “blazing a trail for African 
biotechnology” (Montari et al., 2004). The national 
biotechnology strategy addresses regulatory and legal 
issues as well. It has also “created awareness in 
government departments and agencies of the role of 
biotechnology in meeting health and socio-economic 
needs.” 
The main impetus for legal regulation is section 24 of 
the Constitution, which provides for ‘inter-generational 
equity’, and places an obligation on the state to protect 
the environment for the benefit of present and future 
generations. This provision appears to be limited to 
issues related to biosafety but its scope could be 
extended to the regulation of advances in biotechnology 
that may impact on health and the environment. In line 
with this obligation, the state has enacted a number of 
statutes that are relevant for the regulation of 
biotechnology. Table 2 shows the scope of each statute. 
The discussion in this section focuses more on the 
Genetically Modified Organisms Act for the reasons that 
were mentioned earlier. 
 
 
The Genetically Modified Organisms Act 
 
The Act came into effect on 1st December 1999. It is 
worth noting that the first field trials were allowed in 1994 
and since 1997, several multinational companies were 
allowed to grow and import GMOs even before the GMO 
Act was in place!  This situation has made many critics to 
argue, and rightly so, that the Act “was passed hastily 
and without adequate public participation in order to 
address a situation in which GMOs were already being 
used in agriculture without any effective controls or 
regulatory oversight” (Biowatch, 2004a). The glaring 
omission in this regard is the absence of a concise policy 
framework on which the legal framework can be based. 
Consultation with the relevant stakeholders is an indis-
pensable requirement in the regulation of biotechnology. 
Such consultation ensures that diverse views are consid- 
   




ered so that no stakeholders are left with the feeling that 
there has been regulatory capture by one sector that may 
have vested interests in the biotechnological develop-
ment that is being regulated. 
It has been argued that the regulatory framework 
enshrined in the Act does not “constitute an adequate 
biosafety regime that ensures GMOs are appropriate and 
do not cause harm to the environment, or to human 
health” (Mayet, 2000). The Act is equally limited in scope 
as it only applies to viable living GMOs and not products 
of GMOs. Section 1 of the Act appears to absolve 
developers of GMOs from liability and shifts liability to 
users of GMOs. Such a provision amounts to overprotect-
tion of the biotechnology industry.  
   On 8th October 2004, the Department of Agriculture 
published an amendment Bill for comments (Government 
Gazette No. 26848). The purpose of the amendment is, 
inter alia, to incorporate the provisions of the Cartagena 
Protocol on Biosafety into the Act. In the same way that 
the GMO Act was drafted without public participation, 
there was equally no public involvement in the drafting of 
the amendments. Civil societies have termed the amend-
ments as “an insult to years of civil society engagement 
with the government” (Biowatch, 2004b). The civil society 
has rejected the amendments as inadequate and is 
calling for a complete redraft of the Act after proper public 
consultation. The memorandum and objects to the subse-
quent Bill however shows that all stakeholders’ views that 
were received when the Bill was first published have 
been taken into consideration (Government Gazette 
number 27913 of 26th August 2005). 
The main contention is that the Act and the proposed 
amendments are inconsistent with the constitution and 
other legislations insofar as the Act and the proposed 
amendments do not give effect to the citizens’ rights to 
environmental protection, safe and healthy food, adminis-
trative justice and access to information. 
Other major weaknesses of the Act (and the proposed 
amendments) that have been noted are:   
 
• The precautionary principle is not implemented. 
Section 24 of the Constitution obliges the state to 
protect future generations and this may require the 
state to take precautions when the possible risks of 
science are uncertain. The Section provides as 
follows: 
  
“Everyone has a right- 
 
a) to an environment that is not harmful to their health or 
well-being; and 
b) to have the environment protected, for the benefit of 
present and future generation, through, reasonable 
legislative and other measures that- 
i. Prevent pollution and ecological degradation;  
ii. promote conservation; and 
iii. secure ecologically sustainable development and 





nomic and social development.” 
iv. This principle is equally entrenched in the National 
Environmental Management Act. Section 2 (4) (a) (vii) 
of this Act requires that a risk-averse and cautious 
approach be applied, taking into account the limits of 
current knowledge about the consequences of 
decisions and actions. 
 
• The “polluter pays” principle is not complied with. 
 
This is the case insofar as liability still rests on the 
consumers and farmers. The fact that the issue of liability 
has not been adequately addressed in the Biosafety 
Protocol is not an excuse for having such an unfair 
provision in a national legislation. Besides, the African 
Model Law provides for this issue and this should serve 





The legal framework, which arguably attempts to deal 
with GMOs, is currently contained in the Environmental 
Management and Co-ordination Act. It was enacted in 
1999 and came into force in 2000. It requires 
Environmental Impact assessment (EIA) for certain 
categories of projects. One of such projects that are listed 
under the Act is ‘major developments in biotechnology 
including the introduction and testing of genetically 
modified organisms’. It is not clear whether or not the 
current influx of GMOs in the country were subjected to 
EIA as required under the Act. Plans are underway to 
enact a statute that will deal solely with GMOs and 
biotechnology generally. Much as the Bill is still pending, 
it is worth discussing in this paper since it shows a 
glimmer of the opportunities and limits involved in 




The Biosafety Bill of Kenya (2003) 
 
The Bill was drafted almost three years ago and is yet to 
be tabled in Parliament for debate (Okoth, 2004). 
Analysts fear that “the policy and legal gap has left Kenya 
vulnerable to dumping…supermarkets are bursting with 
imported un-labeled GM products. Even the occasional 
food aid brought to the country is mostly transgenic” 
(Okoth, 2004). Although the government has denied the 
release of GM products to farmers, there is evidence to 
the contrary. For example in the year 2000, Consumer 
Information Network in Kenya “put the US government to 
task over the importation of un-labeled GM yellow maize 
into the country, the US responded that when it is 
exporting to another country, it abides by the rules of that 
country” (Okoth, 2004). 
The Bill is “an Act of Parliament to regulate 
biotechnology and biosafety matters and for connected 
purposes” (Biosafety Bill 2003). A closer look at the  





sections however reveals that the Bill only deals with 
GMOs and not biotechnology as such. The use of the 
term ‘biotechnology’ is equally ambiguous as it is impor-
tant to distinguish between traditional and modern 
biotechnology. The provisions of the Bill are intended to 
be in addition to the requirements imposed by any other 
Act but it does not deal with GMOs that are pharmaceu-
ticals for human use. The other Act that is envisaged in 
this case is the Environmental Management and Co-
ordination Act, which focuses more on environmental law 
generally. 
 The limited scope of the Bill is influenced by the Carta-
gena Protocol, which prescribes the minimum standards 
for parties. It has however been argued that it is “extre-
mely worrying that the Kenyan Bill has not made an ate-
mpt to fully implement the minimum standards establish-
hed by the Protocol” (Comments on the Bill). The Bill thus 
appears to be inconsistent with the Biosafety Protocol 
and the African Model Law. The following main weaknes-
ses have been noted in the comments on the Bill: 
 
• The bill promotes genetic engineering and not 
biosafety. 
• The objectives of the Bill as set out in Clause 4 apply 
to adverse effects on the environment and do not at 
all engage with issues related to biodiversity and 
human health. In particular, the decision of the heads 
of states of the African Union’s meeting in Maputo in 
July 2003 that the African Model Law should be used 
as a basis for developing biosafety regulatory frame-
works has not been complied with. This is the case 
since issues such as traceability and labeling; liability 
and redress are not dealt with in the Bill. The Clause 
only provides for safe transfer and handling. It has 
been argued, and rightly so, that the regulatory 
framework should include “the regulation of import, 
development, transport, handling, packaging,  identi-
fication,  use,  export,  transit, contained use, release 
or placing on the market of GMOs resulting from 
modern biotechnology” (Comments on the Bill). 
• The scope of ‘contained use’ is stretched too far to 
accommodate broad scenarios that may be harmful. 
• The Bill excludes the regulation of living modified 
organisms from its scope yet the Biosafety Protocol 
only excludes the regulation of the transboundary 
movement of such organisms. This is a fundamental 
omission in the Bill. 
• Clause 14(2) relies on the industry’s self-regulation 
insofar as it leaves the industry to determine the 
information that is worth disclosing to the regulatory 
authority in terms of the risks and benefits of GMOs. 
 
 
THE POSSIBILITIES AND LIMITS: AN APPRAISAL 
 
The possibilities and limits of creating appropriate legal 
frameworks for modern biotechnology may be gleaned by 
critically looking at the suitability or otherwise of the  




frameworks that have been discussed in the forgoing 
sections of this paper. These are mainly the Cartagena 
Protocol (at the international level) and the attempts that 
have been made by South Africa and Kenya to develop 
legal frameworks for biotechnology. 
De Greef argues that “the protocol is a poorly informed 
platform, almost devoid of serious inputs from the field of 
reputable biotech and biosafety research…in the 
absence of the scientific community as a stakeholder, 
fringe science and political ideology has taken the place 
of an informed process” (De Greef, 2004). His evidence 
for this argument is as follows: 
 
“At the first meeting of the parties (MOP1) of the 
Cartagena Protocol, there was no representation 
of the scientific community as a stakeholder, as 
against more than 100 representatives from the 
nongovernmental organisation (NGO) community 
with rabidly antiscience and antitechnology 
agenda. The ‘scientific information’ sessions of 
the meeting were dominated by fringe figures who 
have been widely discredited in the scientific 
community, but who, in the absence of a 
reputable voice for science, are seen as the 
providers of scientific information to this process. 
In total, over 20 ‘information sessions’ about 
biotech were organised around the MOP1, most 
of them presenting lurid tales about ‘the existing 
and proven dangers of biotech.’ Not a single 
presentation was made about the promises and 
the benefits of genetically modified (GM) crops.” 
 
 De Greef identifies two main areas in respect of which 
the protocol is a threat to the future of public research of 
GM crops. First, the exchange of research material has 
become more due to the requirement of Advanced 
Informed Agreement (AIA) for import of GM organisms 
intended for release in the environment. This is because 
no distinction is made in the protocol between an 
experimental release and a commercial release. This is 
particularly true of GM plants produced in the European 
Union member states. Second, “the negotiations for 
Liability & Redress regime in the protocol entirely ignore 
the scenario in which the technology developer is say, a 
Consultative Group on International Agriculture Research 
(CGIAR) centre or national university or a governmental 
agency from a developing country. The negotiations are 
likely to use scenarios about the seed sector and the food 
chain familiar to the private sector… and from there to 
extrapolate towards a general requirement for 
containment and segregation of GM and non-GM crops 
that is simply not achievable for most subsistence crops, 
and out of question for crops in centers of genetic 
diversity.” He proposes that a platform of public research 
sector research institutes be created to give a voice to 
their concerns and needs and that the position of public 
goods research sector be defended when considering the 
impact of regulatory options that are debated. 
   




In terms of the main features of the Protocol, the 
exclusion of GMOs that are pharmaceuticals from the 
Protocol’s scope is questionable. This is because 
available information “so far shows that no pharmaceu-
tical for humans are covered by any other agreement or 
organisation in their condition as a GMO and are there-
fore covered by the Protocol” (Institute for Sustainable 
Development and Third World Network, 2000). 
It is clear from the discussion of the selected national 
regimes that both Kenya and South Africa hastily joined 
the league of states that support GMOs without 
appropriate legal and policy frameworks in place. On 23rd 
June 2004, the President of the Republic of Kenya 
opened a greenhouse facility located at Kenya Agricultu-
ral Research Institute (KARI). This was reported as an 
official government endorsement of GMOs in the country. 
In his speech he stated that the development of a policy 
for biotechnology research and the use of the resultant 
products were at an advanced stage and that Bills to 
support the policy were being prepared for consideration 
by Parliament. Analysts have wondered “under what 
policy and legal regime then is the greenhouse built and 
maintained?” (Makoloo, 2004). 
There are possibilities and limits in developing legal 
frameworks for modern biotechnology. The limits ema-
nate from the fact that the legal framework cannot be 
used in isolation without properly reckoning with the 
societal spheres that influence the legislative process. All 
the factors that influence such societal spheres must in 
turn be accorded the appropriate importance that they 
deserve. This can be achieved if all views are taken into 
account through public discourse, which often precedes 
public policy formulation from which policy frameworks 
that are useful in legislation can be based. Proper choice 
of policy options determines the effectiveness of regula-
tions. For this reason, any regulations that are not prece-
ded by proper policy development are bound to be limited 





What emerges from the foregoing discussion is that the 
biotechnology industry is not easy to regulate because 
biotechnology is a dynamic field thus, as Gale correctly 
notes, “laws governing such [a] field[s] to be effective, 
must change, adapt and evolve as the field changes, 
adapts and evolves” (Gale, 1993).The main factors to be 
considered in developing regulatory frameworks for 
biotechnology are: 
 
• Broader public consultation that considers all relevant 
stakeholders’ views. 
• Maintaining flexibility without losing credibility. 
• Establishment of a concise policy framework on 
which the legal framework can be based.  
My proposal is that the development of legal regulatory 





frameworks. For example, at national levels, there should 
be consultation with stakeholders and transparency as 
well. It is equally important to acknowledge and 
appropriately utilise the shared functions of different 
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